| Market Cap | 9.63M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -19.8M | Forward P/E | 2.63 | EPS next Y | - | 50D Avg Chg | -9.00% |
| Sales | 17.42M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -41.00% |
| Dividend | N/A | Price/Book | 0.25 | EPS next 5Y | - | 52W High Chg | -81.00% |
| Recommedations | 3.00 | Quick Ratio | 1.53 | Shares Outstanding | 1.75M | 52W Low Chg | 36.00% |
| Insider Own | 12.39% | ROA | -23.39% | Shares Float | 1.63M | Beta | 1.53 |
| Inst Own | 7.39% | ROE | -61.27% | Shares Shorted/Prior | 20.09K/16.81K | Price | 0.21 |
| Gross Margin | 37.64% | Profit Margin | -102.77% | Avg. Volume | 195,798 | Target Price | - |
| Oper. Margin | -105.91% | Earnings Date | May 9 | Volume | 93,817 | Change | -4.11% |
Clever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hague Henry R III | Chief Financial Offi.. Chief Financial Officer | Feb 22 | Sell | 0.4402 | 9,728 | 4,282 | 209,204 | 02/24/23 |
| Fajardo Andres | Chief Executive Offi.. Chief Executive Officer | Jan 17 | Sell | 0.4006 | 57,669 | 23,102 | 525,934 | 01/19/23 |
| Wilches Julian | Chief Regulatory Off.. Chief Regulatory Officer | Jan 17 | Sell | 0.4006 | 4,557 | 1,826 | 48,018 | 01/19/23 |
| Fajardo Andres | Chief Executive Offi.. Chief Executive Officer | Dec 20 | Sell | 0.34 | 5,133 | 1,745 | 583,603 | 12/22/22 |
| Wilches Julian | Chief Regulatory Off.. Chief Regulatory Officer | Dec 20 | Sell | 0.34 | 3,829 | 1,302 | 52,575 | 12/22/22 |
| Wilches Julian | Chief Regulatory Off.. Chief Regulatory Officer | Jul 06 | Sell | 1.03 | 288 | 297 | 56,404 | 07/06/22 |
| Kastin David | General Counsel General Counsel | Jul 06 | Sell | 1.03 | 565 | 582 | 172,151 | 07/06/22 |
| Hague Henry R III | Chief Financial Offi.. Chief Financial Officer | Jul 06 | Sell | 1.03 | 598 | 616 | 218,932 | 07/06/22 |
| Fajardo Andres | Chief Executive Offi.. Chief Executive Officer | Jul 06 | Sell | 1.03 | 1,170 | 1,205 | 588,736 | 07/06/22 |